Direct Biologics Reports Compelling Results From Phase 2 Trial With ExoFlo in Hospitalized Patients With Respiratory Failure or Moderate-to-Severe Acute Respiratory Distress Syndrome Due to COVID-19
ARDSDelisted Stock | USD 0.27 0.02 8.00% |
Slightly above 55% of Aridis Pharmaceuticals' private investors are presently thinking to get in. The analysis of overall sentiment of trading Aridis Pharmaceuticals pink sheet suggests that some investors are interested at this time. Aridis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Aridis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Aridis Pharmaceuticals pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Aridis daily returns and investor perception about the current price of Aridis Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
Aridis |
AUSTIN, Texas, March 14, 2023--Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles derived from bone marrow mesenchymal stem cells to address multiple disease indications, announced favorable safety, dosing and efficacy results from its Phase 2 clinical trial of ExoFlo in hospitalized adult COVID-19 patients with moderate-to-severe acute respiratory distress syndrome .
Read at finance.yahoo.com
Aridis Pharmaceuticals Fundamental Analysis
We analyze Aridis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aridis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aridis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Aridis Pharmaceuticals is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Aridis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aridis Pharmaceuticals pink sheet to make a market-neutral strategy. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aridis Pharmaceuticals Related Equities
RVPH | Reviva Pharmaceuticals | 8.77 | ||||
AKTX | Akari Therapeutics | 8.04 | ||||
ADTX | Aditxt | 6.06 | ||||
ATXI | Avenue Therapeutics | 4.37 | ||||
ABVC | ABVC Biopharma | 3.92 | ||||
RNAZ | Transcode Therapeutics | 2.94 | ||||
DRMA | Dermata Therapeutics | 2.73 | ||||
KOD | Kodiak Sciences | 1.83 | ||||
UNCY | Unicycive Therapeutics | 1.47 | ||||
REVB | Revelation Biosciences | 1.33 | ||||
HOTH | Hoth Therapeutics | 1.20 | ||||
NRBO | Neurobo Pharmaceuticals | 0.43 | ||||
CGTX | Cognition Therapeutics | 2.44 | ||||
ZVSA | ZyVersa Therapeutics | 3.60 | ||||
RVPHW | Reviva Pharmaceuticals | 4.35 | ||||
VRAX | Virax Biolabs | 4.83 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
CEOs Directory Screen CEOs from public companies around the world | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |